Beachbody Company (BODI): +37% Surge in 30 Days on Earnings Strength and Product Momentum
Key Takeaways
- BODI stock surged +37% over the past 30 days, driven by positive analyst sentiment and product launches amid a volatile but upward trend.
- Over the past quarter, the stock rose +26%, reflecting sustained profitability from recent earnings beats and strategic business shifts.
- Key drivers include Q4 2025 earnings with net income and positive EBITDA, analyst upgrades signaling up to 33% upside, and new P90X supplements boosting market sentiment.
- Transition from multi-level marketing to omni-channel model improved margins despite revenue declines, supporting stock resilience.
- Strong relative performance versus consumer discretionary peers highlights improving fundamentals and growth outlook.
Understanding Beachbody Company (BODI) and Its Place in the Market
The Beachbody Company, Inc. (BODI) stands out as a key player in fitness and nutrition, delivering digital subscription platforms like BODi for workouts, nutrition plans, and connected fitness equipment. In my view, the shift from its original multi-level marketing (MLM) structure to an omni-channel model—focusing on direct-to-consumer digital subscriptions, retail nutrition products, and affiliate marketing—has been pivotal. Operating in the tough health and wellness space, BODI goes head-to-head with names like Peloton and PTON, but sets itself apart with iconic brands like P90X and lean operations. This evolution has strengthened its fundamentals, evidenced by higher gross margins of 74.5% in Q4 2025 and positive cash flow, which I see as the core reason behind the recent stock price gains as investors recognize these profitability improvements.
BODI's Recent Stock Performance: 30 Days and Quarterly View
Looking at the numbers, BODI stock has climbed +37% over the last 30 days, moving from a closing price of about $8.68 to $11.90. The path has been volatile yet upward-trending, with notable surges tied to earnings and news, followed by some pullbacks. Over the past quarter, shares advanced +26% from around $9.42, demonstrating a steady recovery even as broader markets stayed choppy. The 50-day range of $6.96 to $12.31 captures that range-bound volatility leading into recent highs. What stands out is how BODI outperformed the S&P 500 and the consumer discretionary sector, pointing to company-specific drivers rather than just macro influences.
Key Factors Behind BODI's 30-Day Rally
From what I see, the 30-day rally in BODI was fueled by growing analyst optimism and fresh product moves. Wall Street coverage pointed to upside potential as high as 33.52%, with consensus targets suggesting 29.83% gains, all tied to earnings momentum. The rollout of P90X Performance Supplements, featuring advanced "P90X-Factor" ingredients for workouts and recovery, lifted brand visibility and optimism around retail growth. This contributed to a 6.1% single-day jump, reflecting wider confidence in FY2026 prospects. Outpacing consumer discretionary peers further drew buyers in choppy markets, with relative strength playing a clear role. I also checked this using Tickeron’s AI Screener to confirm how the stock stacks up against industry peers. These elements directly linked to price spikes, such as the post-earnings move from $8.33 to $10.91 around March 11.
What Powered BODI's +26% Quarterly Gain
The quarter's +26% rise for BODI rested on ongoing profitability stories from Q4 and full-year 2025 results—the first full year of positive operating income since 2021. Even with a 35.7% revenue decline to $55.5 million, stemming from exiting MLM and connected fitness, net income reached $5.2 million for the second straight quarter, while adjusted EBITDA climbed 48% to $12.9 million, exceeding guidance. Gross margins grew 400 basis points to 74.5% through cost controls and the omni-channel pivot. Institutional attention picked up, backed by a Zacks Rank #2 (Buy) and gains against peers down 7.4% YTD. Broader wellness trends and a lower breakeven point from expense reductions offered support, with back-to-back earnings beats—like Q3 EPS of $0.51 versus -$0.54 expected—propelling the trajectory.
Exploring Trending AI Robots for Smarter Trading
In my own research workflow, I often turn to Tickeron’s Trending AI Robots page, which highlights the platform's top-performing AI trading bots out of hundreds available. These bots scan and trade thousands of tickers across markets, using strategies like trend-following, mean reversion, or momentum across short-term, swing, or long-term horizons. Performance stats such as win rate, profit factor, and Sharpe ratio are laid out clearly, making it straightforward to pick ones aligned with conditions like volatility in consumer stocks. This curated view of recent standouts has helped me incorporate data-driven automation effectively—worth a look if you're building out your trading tools.
Looking Ahead: What to Watch for BODI Stock
I'm watching Q1 2026 earnings closely for updates on nutrition retail progress and BODi digital subscriber growth, which stood at 0.87 million in Q4. Further product pushes, including more affordable nutrition SKUs and P90X refreshes, could mark an FY2026 revenue turning point. Keep an eye on at-home fitness demand, rivalry from PTON, and macro elements like consumer spending in a higher-rate world. Risks involve seasonal swings—stronger in Q1-Q2—and executing the omni-channel shift; on the flip side, additional analyst upgrades or solid free cash flow guidance could shift sentiment further.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full Disclaimers and Limitations.
Momentum Indicator for BODI turns positive, indicating new upward trend
BODI saw its Momentum Indicator move above the 0 level on April 17, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 96 similar instances where the indicator turned positive. In of the 96 cases, the stock moved higher in the following days. The odds of a move higher are at .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for BODI just turned positive on April 17, 2026. Looking at past instances where BODI's MACD turned positive, the stock continued to rise in of 50 cases over the following month. The odds of a continued upward trend are .
BODI moved above its 50-day moving average on April 08, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for BODI crossed bullishly above the 50-day moving average on March 18, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 20 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where BODI advanced for three days, in of 228 cases, the price rose further within the following month. The odds of a continued upward trend are .
BODI may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The 10-day RSI Indicator for BODI moved out of overbought territory on March 19, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 17 similar instances where the indicator moved out of overbought territory. In of the 17 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BODI declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. BODI’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.863) is normal, around the industry mean (30.117). P/E Ratio (0.000) is within average values for comparable stocks, (75.645). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (21.362). Dividend Yield (0.000) settles around the average of (0.030) among similar stocks. P/S Ratio (0.346) is also within normal values, averaging (51.132).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BODI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
Advertisement